PRECIGEN, INC. PGEN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-50.41
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $9.7M | -$250.6M | — | -$89.8M | $20.9M |
| 2024 | $3.9M | -$126.2M | — | -$76.8M | $38.5M |
| 2023 | $6.2M | -$95.9M | — | -$68.5M | $118.5M |
| 2022 | $26.9M | $28.3M | — | -$70.0M | $126.3M |
| 2021 | $14.3M | -$92.2M | — | -$63.0M | $107.3M |
| 2020 | $32.0M | -$170.5M | — | -$84.5M | $67.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Thomasian Harry Jr. | Chief Financial Officer | 2026-05-28 | Sell | 41,884 | $4.36 |
| Tennant Phil | Chief Commercial Officer | 2026-05-28 | Sell | 30,272 | $4.36 |
| Shah Rutul R | Chief Operating Officer | 2026-05-28 | Sell | 42,703 | $4.36 |
| Lehr Donald P. | Chief Legal Officer | 2026-05-28 | Sell | 29,131 | $4.36 |
| Sabzevari Helen | President and CEO | 2026-05-28 | Sell | 119,250 | $4.36 |
| Thomasian Harry Jr. | Chief Financial Officer | 2026-05-23 | Option exercise | 87,500 | — |
| Tennant Phil | Chief Commercial Officer | 2026-05-23 | Option exercise | 62,500 | — |
| Shah Rutul R | Chief Operating Officer | 2026-05-23 | Option exercise | 90,000 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -50.41 (distress)
- Working capital / assets 0.501
- Retained earnings / assets -15.056
- EBIT / assets -0.711
- Equity / liabilities 0.155
Source: SEC EDGAR filings · CIK 0001356090 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.